Home › Research › Topics › acetylcholinesterase
acetylcholinesterase
234 studies tagged acetylcholinesterase, dated 1977-11-01 to 2026-10-25. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study 2026-10-25
- Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling 2026-10-20
- DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer’s Disease Patient-Derived Neurons 2026-10-18
Studies
234 studies carry this tag.
Date range
1977 to 2026
Top journals
- Research Square 9
- Journal of medicinal chemistry 7
- International journal of molecular sciences 6
- Journal of Alzheimer's disease : JAD 6
- Nature reviews. Drug discovery 6
154 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
41/100
Alzheimer's disease (AD) is the most common form of dementia, with a high impact worldwide, accounting for more than 46 million cases.
-
Drug repositioning or repurposing is the process of discovering leading-edge indications for authorized or declined/abandoned molecules for use in different diseases.
-
Alzheimer's Disease (AD) is characterized as a progressive neurodegenerative disease most commonly associated with memory deficits and cognitive decline.
-
Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors represents the main available approach to treat cognitive and behavioural symptoms of the early as well as late stages of Alzheimer's disease.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common type of dementia.
-
Neurodegenerative disorders are primarily characterized by neuron loss.
-
A reduced removal of dysfunctional mitochondria is common to aging and age-related neurodegenerative pathologies such as Alzheimer's disease (AD).
-
41/100
Acetylcholinesterase (AchE), hydrolase enzyme, regulates the hydrolysis of acetylcholine neurotransmitter in the neurons.
-
Fosgonimeton and placebo were shown to be safe and well-tolerated across all doses.
-
43/100
RNA therapeutics comprise a diverse group of oligonucleotide-based drugs such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short hairpin RNAs (shRNAs) that can be designed to selectively interact with drug targets currently undruggable with small molecule-based drugs or monoclonal antibodies.
-
Alzheimer's disease (AD) presents a complex pathology entangling numerous pathological factors, including amyloid-β (Aβ), metal ions, and reactive oxygen species (ROS).
-
Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for most cases of dementia.
-
Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex, multifactorial, unalterable, and progressive in nature.
-
The effects of LRGT on animal models show significant benefits in AD pathology and cognitive impairment.
-
Alzheimer's disease (AD), is the most common type of dementia primarily affecting the later years of life.
-
Butyrylcholinesterase (BChE) is an essential human cholinesterase relevant to liver conditions and neurodegenerative diseases, which makes it a pivotal biomarker of health.
-
Herein, combined with a pervasive smartphone installed with a color recognition app, dual-responsive CDs@Eu/GMP ICPs were designed as a red-to-blue paper-based colorimetric sensor for the point-of-use analysis of cerebral acetylcholinesterase (AChE) upon Cd2+ exposure.
-
The aim of this work is to review tacrine analogues from the last three years, which were not included in the latest review work, donepezil and galantamine hybrids from 2015 and rivastigmine derivatives from 2014.
-
The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaicin results in compounds with nanomolar potencies toward human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) that retain or improve the antioxidant properties of capsaicin.
-
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations.
-
Comparing with the placebo group (n = 83, change - 1.45), the ADAS-cog12 score change in the GV-971 600-mg group (n = 76) was - 1.39 (p = 0.89) and the GV-971 900-mg group (n = 83) was - 2.58 (p = 0.30).
-
Alzheimer's disease (AD) is a multifactorial disease characterized by the presence of amyloid plaques, neurofibrillary tangles, and nerve cell death that affects, mainly, older people.
-
Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly population worldwide.
-
Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance cholinergic neurotransmission as the first line of treatment against Alzheimer's disease (AD).
-
Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research.
-
Alzheimer's disease (AD) is a debilitating neurodegenerative disease that causes a progressive decline in memory, language and problem solving.
-
This review is devoted to comparative pharmacological analysis of synthetic drugs such as memantine and its isomers, as well as tacrine, velnacrine, rivastigmine, and donepezil, with natural alkaloids, terpenoids, and triterpenoid peroxides, which are used to treat dementia, Alzheimer's and Parkinson's diseases, myasthenia gravis and other neurodegenerative diseases.
-
Alzheimer's disease (AD) is an enormous healthcare challenge, and 50 million people are currently suffering from it.
-
Alzheimer's disease is a neuropathological disease with symptoms such as language problems, confusion as to place or time, loss of interest in activities, which were previously enjoyed, behavioral changes, and memory loss.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid β in the form of extracellular plaques and by intracellular neurofibrillary tangles, with eventual neurodegeneration and dementia.
-
Computational drug repurposing has the ability to remarkably reduce drug development time and cost in an era where these factors are prohibitively high.
-
Antisense oligonucleotides represent a novel therapeutic platform for the discovery of medicines that have the potential to treat most neurodegenerative diseases.
-
In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters.
-
Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic event correlated with cognitive impairment.
-
Novel drug development is onerous, time consuming and overpriced process with particularly low success and relatively high enfeebling rates.
-
Alzheimer's disease (AD) is a main cause of dementia, accounting for up to 75% of all dementia cases.
-
An increase in dementia numbers and global trends in population aging across the world prompts the need for new medications to treat the complex biological dysfunctions, such as neurodegeneration associated with dementia.
-
Cholinergic synapses are ubiquitous in the human central nervous system.
-
Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered as one of the most intractable medical problems with heavy social and economic costs.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically accepted treatment to cure or halt its progression.
-
However, there is also some limitation associated with IN like poor drug permeation through the nasal mucosa and mucociliary clearance.
-
Neurodegenerative diseases are increasing in number, given that the general global population is becoming older.
-
The NMDA (N-methyl-D-aspartate) receptor transduces the binding of glutamate and glycine, coupling it to the opening of a calcium-permeable ion channel 1 .
-
The production parameters were optimized by design of experiments.
-
Due to the vast differences in chemical properties among small molecule drugs, nucleotide drugs, and superparamagnetic iron oxide nanocubes (SPIONs), such as charge and hydrophobicity, entrapment of these within a single carrier for traceable synergistic therapy has been proven difficult.
-
39/100
Over the past decades, a frequent co-morbidity of cerebrovascular pathology and Alzheimer's disease has been observed.
-
Rifampicin exerts significant brain protective functions in multiple experimental models.
-
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brain of extracellular amyloid-β protein (Aβ) and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein.
-
In the process of drug development, in vitro studies do not always adequately predict human-specific drug responsiveness in clinical trials.
-
G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiology and their pharmacological tractability.
From across this tag
7 of the 234 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.
- Checks and balances on cholinergic signaling in brain and body function
- Drug repurposing using meta-analysis of gene expression in Alzheimer's disease
- Dual Drug Repurposing: The Example of Saracatinib
- Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders
- Human neuronal nicotinic receptors
- No response to high-dose muscarinic agonist therapy in Alzheimer's disease
- Alzheimer disease, attention, and the cholinergic system